Generic Duaklir Pressair Availability
Last updated on Dec 12, 2024.
Duaklir Pressair is a brand name of aclidinium/formoterol, approved by the FDA in the following formulation(s):
DUAKLIR PRESSAIR (aclidinium bromide; formoterol fumarate - powder, metered;inhalation)
-
Manufacturer: COVIS
Approval date: March 29, 2019
Strength(s): 0.4MG/INH;0.012MG/INH [RLD]
Has a generic version of Duaklir Pressair been approved?
No. There is currently no therapeutically equivalent version of Duaklir Pressair available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duaklir Pressair. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dosage and formulation
Patent 10,085,974
Issued: October 2, 2018
Inventor(s): Casado Rosa Lamarca & Serra Gonzalo De Miquel
Assignee(s): Almirall, S.A.The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Patent expiration dates:
- March 13, 2029✓✓
- March 13, 2029
-
Dosage and formulation
Patent 11,000,517
Issued: May 11, 2021
Inventor(s): Casado Rosa Lamarca & Serra Gonzalo De Miquel
Assignee(s): Almirall, S.A.The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Patent expiration dates:
- March 13, 2029✓✓
- March 13, 2029
-
Patent 8,051,851
Patent expiration dates:
- April 22, 2027✓
- April 22, 2027
-
Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Patent RE46417
Issued: May 30, 2017
Inventor(s): Fernandez Forner Dolors & Prat Quiñones Maria & Buil Albero Maria Antonia
Assignee(s): Almirall, S.A.A compound according to formula (I)
Patent expiration dates:
- February 10, 2025✓✓✓
- February 10, 2025
More about Duaklir Pressair (aclidinium / formoterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bronchodilator combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.